BlueRock Therapeutics
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues
Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s
The US-based company develops light-based therapies for neurodegenerative conditions
TRIMTECH Therapeutics establishes Scientific Advisory Board
Alessio Ciulli has been appointed as Chair of the board
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year
Bayer’s Kerendia granted FDA approval for new heart failure indication
Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours
The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform